Related Experiment Videos
Experience with triple-drug therapy in a pharmacological erection program
F E Govier1, R D McClure, R M Weissman
1Department of Urology, Virginia Mason Medical Center, Seattle, Washington.
The Journal of Urology
|December 1, 1993
Summary
Triple-drug therapy, a combination of papaverine, phentolamine, and prostaglandin E1, effectively treats erectile dysfunction. This approach demonstrated a low incidence of side effects like priapism, pain, and scarring in a clinical study.
Area of Science:
- Urology
- Andrology
- Pharmacology
Background:
- Erectile dysfunction (ED) affects a significant number of men.
- Pharmacological interventions are a key component in managing ED.
- Intracorporeal injections offer a direct treatment method for ED.
Purpose of the Study:
- To evaluate the efficacy and safety of triple-drug therapy for erectile dysfunction.
- To assess the long-term outcomes of intracorporeal triple-drug therapy.
- To determine the optimal agent for pharmacological erection programs.
Main Methods:
- A cohort of 170 impotent men received intracorporeal injections of papaverine, phentolamine, and prostaglandin E1.
- 146 patients were enrolled in a long-term pharmacological erection program.
- Data on injection volume, duration of treatment, and adverse events were collected.
Main Results:
- Usable erections were achieved in all participants.
- The average treatment duration was 11.2 months.
- Low incidences of priapism (1.7%), scarring (4.2%), and pain (3.5%) were reported.
Conclusions:
- Triple-drug therapy is an effective and safe treatment for erectile dysfunction.
- The combination offers a superior dose response with minimal adverse effects.
- This therapy is recommended as a primary agent in pharmacological ED management.